Cite
Martínez-Sánchez MV, Periago A, Legaz I, et al. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2015;5(4):e1093721doi: 10.1080/2162402X.2015.1093721.
Martínez-Sánchez, M. V., Periago, A., Legaz, I., Gimeno, L., Mrowiec, A., Montes-Barqueros, N. R., Campillo, J. A., Bolarin, J. M., Bernardo, M. V., López-Álvarez, M. R., González, C., García-Garay, M. C., Muro, M., Cabañas-Perianes, V., Fuster, J. L., García-Alonso, A. M., Moraleda, J. M., Álvarez-Lopez, M. R., & Minguela, A. (2016). Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology, 5(4), e1093721. https://doi.org/10.1080/2162402X.2015.1093721
Martínez-Sánchez, María V, et al. "Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing." Oncoimmunology vol. 5,4 (2016): e1093721. doi: https://doi.org/10.1080/2162402X.2015.1093721
Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, Campillo JA, Bolarin JM, Bernardo MV, López-Álvarez MR, González C, García-Garay MC, Muro M, Cabañas-Perianes V, Fuster JL, García-Alonso AM, Moraleda JM, Álvarez-Lopez MR, Minguela A. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2015 Oct 29;5(4):e1093721. doi: 10.1080/2162402X.2015.1093721. eCollection 2016 Apr. PMID: 27141379; PMCID: PMC4839374.
Copy
Download .nbib
